AbbVie Hits Last Generic-Orilissa Holdout With New Patent Suit

AbbVie Inc. expanded its effort to block copies of the endometriosis drug Orilissa, suing Hetero Labs Ltd. over a recently issued patent that won’t expire for another 13 years.

Hetero’s proposed generic 150- and 200-milligram tablets of Orilissa’s active ingredient, elagolix sodium, infringe US Patent No. 12,102,637, issued Oct. 1 and licensed from Neurocrine Biosciences Inc., according to a complaint filed Monday in the US District Court for the District of Delaware.

Hetero is the lone defendant remaining out ofnine that were targeted in an October 2022 case in Delaware district court that is set for a June ...